Status:
COMPLETED
Levothyroxine (L-T4) Absorption After Bariatric Surgery
Lead Sponsor:
University of Sao Paulo
Conditions:
Morbid Obesity
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Intestinal absorption of levothyroxine (LT4) tablets depends on its dissolution in gastric acid secretion, which is reduced after bariatric interventions. Impaired LT4 absorption due to low gastric di...
Detailed Description
LEVOTHYROXINE ABSORPTION IN MORBIDLY OBESE PATIENTS BEFORE AND AFTER ROUX-EN-Y BARIATRIC SURGERY INTRODUCTION Levothyroxine sodium (LT4) is an effective drug prescribed as replacement therapy for pati...
Eligibility Criteria
Inclusion
- morbidly obese individual (body mass index (BMI)≥40 Kg/m2)
- individuals for whom bariatric surgery is indicated
- patients who had undergone Roux-en-Y bariatric surgery 2 to 3 months before inclusion in the study
Exclusion
- previous diagnosis of thyroid cancer
- diabetes mellitus in use of insulin
- chronic or atrophic gastritis
- use of medications associated with impaired LT4 absorption.
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01189344
Start Date
September 1 2007
End Date
July 1 2010
Last Update
August 26 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital das Clínicas da Universidade de São Paulo
São Paulo, São Paulo, Brazil